Jerzy Zaluski
Overview
Explore the profile of Jerzy Zaluski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
2181
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martin M, Segui M, Anton A, Ruiz A, Ramos M, Adrover E, et al.
N Engl J Med
. 2010 Dec;
363(23):2200-10.
PMID: 21121833
Background: A regimen of docetaxel, doxorubicin, and cyclophosphamide (TAC) is superior to a regimen of fluorouracil, doxorubicin, and cyclophosphamide (FAC) when used as adjuvant therapy in women with node-positive breast...
2.
Contribution of artificial intelligence to the knowledge of prognostic factors in Hodgkin's lymphoma
Bucinski A, Marszall M, Krysinski J, Lemieszek A, Zaluski J
Eur J Cancer Prev
. 2010 May;
19(4):308-12.
PMID: 20473182
Hodgkin's lymphoma is one of the most curable malignancies and most patients achieve a lasting complete remission. In this study, artificial neural network (ANN) analysis was shown to provide significant...
3.
Curran D, Pozzo C, Zaluski J, Dank M, Barone C, Valvere V, et al.
Qual Life Res
. 2009 Jul;
18(7):853-61.
PMID: 19568958
Purpose: The quality of life (QL) of advanced gastric cancer patients receiving irinotecan, folinic acid and 5-fluorouracil (5-FU) (IF arm) or cisplatin with 5-FU (CF arm) is presented. Methods: Patients...
4.
Van Cutsem E, Kohne C, Hitre E, Zaluski J, Chang Chien C, Makhson A, et al.
N Engl J Med
. 2009 Apr;
360(14):1408-17.
PMID: 19339720
Background: We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought associations between the mutation status of the KRAS...
5.
Wysocki P, Korski K, Lamperska K, Zaluski J, Mackiewicz A
Med Sci Monit
. 2008 Jul;
14(7):SC7-10.
PMID: 18591931
Background: Docetaxel is a member of the taxoid anticancer agents routinely used in the treatment of high-risk or metastatic breast cancer. A recent study demonstrated that a low response rate...
6.
Twelves C, Wong A, Nowacki M, Abt M, Burris 3rd H, Carrato A, et al.
N Engl J Med
. 2005 Jul;
352(26):2696-704.
PMID: 15987918
Background: Intravenous bolus fluorouracil plus leucovorin is the standard adjuvant treatment for colon cancer. The oral fluoropyrimidine capecitabine is an established alternative to bolus fluorouracil plus leucovorin as first-line treatment...
7.
Nabholtz J, Falkson C, Campos D, Szanto J, Martin M, Chan S, et al.
J Clin Oncol
. 2003 Mar;
21(6):968-75.
PMID: 12637459
Purpose: This randomized, multicenter, phase III study compared doxorubicin and docetaxel (AT) with doxorubicin and cyclophosphamide (AC) as first-line chemotherapy (CT) in metastatic breast cancer (MBC). Patients And Methods: Patients...